Odysight.ai Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Consolidated Financial Statements
NOTE 1 –GENERAL:
| a. | Odysight.ai Inc (the “Company”) was incorporated under the laws of the State of Nevada on March 22, 2013. |
| The Company’s wholly owned subsidiary, Odysight.ai Ltd (“Odysight.ai”), was incorporated in the State of Israel on January 3, 2019, and was merged into the Company on December 31, 2019 in a share exchange transaction, following which the surviving operations of the merged entity were the operations of Odysight.ai. | |
| On February 28, 2024, D. VIEW Ltd., a wholly owned subsidiary of the Company was incorporated in the State of Israel to act as a local representative for the defense market in Israel. | |
| On January 9, 2025, Odysight.Ai Eu S.r.l., a wholly owned subsidiary of the Company was incorporated under the laws of Italy. | |
| References to the Company include the subsidiaries unless the context indicates otherwise. | |
| The Company, through its subsidiaries, provides vision-based platform solutions for the Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets with its visualization and AI platform. The Company’s video sensor-based solutions and its embedded software, and AI algorithms are deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases and allow maintenance and operations teams visibility into areas which are inaccessible under normal operation, or where the operating ambience is not suitable for continuous real-time monitoring. Some of the Company’s products utilize micro visualization technology in medical devices for minimally invasive medical procedures. In February 2025, we closed a public offering generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting commissions and estimated offering expenses. After deducting issuance costs, the Company received proceeds of approximately $20.9 million. For additional information see note 5(a)(4). | |
| On February 11, 2025, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “ODYS”. Prior to such date, the Company was quoted on the OTCQB under the same symbol. |
-12-
NOTE 1 – GENERAL(continued):
| b. | Since incorporation of Odysight.ai and through June 30, 2025, the Company accumulated a deficit of approximately $54.3 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these interim condensed financial statements. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations, requiring the Company to obtain additional funding to continue its future operations until becoming profitable. |
| c. | On June 13, 2025, Israel launched “Operation Rising Lion” with a surprise attack on Iran, including precision strikes on weapon and nuclear facilities. In response to Israel’s attack, Iran launched retaliatory strikes on Israel, which included significant ballistic missiles and unmanned aerial vehicles fired towards both military and civilian targets in Israel. The attacks resulted in Israeli civilian casualties and property damage. Consequently, Israel’s Home Front Command announced a “special home front situation” and imposed stricter safety guidelines than had previously been in place, such as restricting public gatherings and passenger flights to and from Israel, and the temporary closure of certain businesses, which led to a decrease in market and economic activity in Israel. As a result of these guidelines, the Company’s offices in Israel were closed on certain days during this period. The Company does not expect a substantial impact on its operations from the above-described events. |
NOTE 2 –BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
a. Unaudited Interim Financial Statements
The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
b. Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
c. Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment and stock-based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
-13-
NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES(continued):
d. Significant Accounting Policies
The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.
NOTE 3 –LEASES:
| a. | Omer office space |
In December 2020, Odysight.ai entered into a lease agreement for office space in Omer, Israel (the “original space”), with the 36-month term for such agreement beginning on January 1, 2021. In March 2021, Odysight.ai entered into a lease agreement for additional office space in Omer, Israel (the “additional space”), with the term for such agreement ending December 31, 2023.
On June 25, 2023, Odysight.ai entered into an amendment to these agreements, pursuant to which the lease for the additional space was shortened and ended on June 30, 2023 and the lease for the original space was extended for an additional five years until December 31, 2028. It was also agreed that Odysight.ai has an option to terminate the agreement for the original space after three years. Odysight.ai expects that the lease period will be three years.
Monthly lease payments under the agreement for the original space are approximately $7 thousand.
| b. | Ramat Gan office space |
In May 2023, Odysight.ai entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 48 months beginning on July 1, 2023 and the Company has an option to extend the lease period for an additional two years. The Company currently does not expect to extend the lease period. Monthly lease payments under the agreement are approximately $25 thousand.
Odysight.ai subleases part of the office space in Ramat Gan to a third party for approximately $8 thousand per month.
| c. | The Company leases vehicles for the use of certain of its employees in Israel. The lease terms are typically three-year periods. |
Supplemental cash flow information related to operating leases was as follows:
| Six months ended June 30, | Three months ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Unaudited | ||||
| USD in thousands | ||||
| Cash paid for amounts included in the measurement of lease liabilities | 296 | 297 | 149 | 146 |
As of June 30, 2025, the Company’s operating leases had a weighted average remaining lease term of 0.60 years and a weighted average discount rate of 6% for vehicles and 12.8% for offices.
The maturities of lease liabilities under operating leases as of June 30, 2025, are as follows:
| Operating leases | |
|---|---|
| USD in thousands | |
| Remainder of 2025 | 301 |
| 2026 | 505 |
| 2027 | 201 |
| 2028 | 3 |
| Total future lease payments | 1,010 |
| Less imputed interest | (91) |
| Total lease liability balance | 919 |
-14-
NOTE 4 –OTHER CURRENT LIABILITIES:
Other current liabilities consisted of the following:
| June, 2025 | December 31, 2024 | |
|---|---|---|
| USD in thousands | ||
| Government authorities | 85 | 79 |
| Accrued expenses | 326 | 261 |
| Other payables | 28 | 28 |
| Total other current liabilities | 439 | 368 |
NOTE 5 –EQUITY:
| a. | Private Placement |
|---|---|
| 1. | On March 29, 2021, the Company issued to certain investors, including Moshe (Mori) Arkin, a major stockholder and director of the Company, an aggregate of 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consisted of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until March 31, 2026 and subject to customary adjustments. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of the Company’s common stock equals or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise. |
| 2. | On March 16, 2023, the Company entered into stock purchase agreements for a private placement with (i) Moshe (Mori) Arkin and (ii) The Phoenix Insurance Company Ltd. (“Phoenix Insurance”) and Shotfut Menayot Israel – Phoenix Amitim (“Phoenix Amitim”), in connection with the sale and issuance of an aggregate of 3,294,117 units, at a purchase price of $4.25 per unit, and for an aggregate purchase price of $14 million. Each unit consisted of: (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of the Company’s common stock. The warrants are immediately exercisable, expire three years from the date of issuance and are subject to customary adjustments. |
| 3. | On July 16, 2024, the Company issued 2,144,583 shares of its common stock in consideration for a purchase price of $4.80 per share to new and existing investors, including Moshe (Mori) Arkin and The Phoenix Holdings, through Phoenix Insurance and Phoenix Amitim (the “2024 Private Placement”). The Company raised approximately $10.3 million (gross) in the 2024 Private Placement. After deducting issuance costs, the Company received proceeds of approximately $9.8 million. |
| 4. | On February 12, 2025, the Company completed a U.S. underwritten public offering issuing 3,307,692 shares of the Company’s common stock at a price of $6.50 per share. The Company also granted the underwriters a 30-day over-allotment option to purchase up to an additional 496,153 shares at a purchase price of $6.50 per share. On February 14, 2025, the Company sold an additional 345,432 shares of common stock as a result of a partial exercise of the over-allotment option at the public offering price of $6.50 per share. Following the exercise of the over-allotment option, the Company sold a total of 3,653,124 shares of common stock, generating gross proceeds of approximately $23.7 million, prior to the deduction of underwriting discounts, commissions and estimated offering expenses. After deducting issuance costs, the Company received proceeds of approximately $20.9 million. |
Warrants:
As of June 30, 2025, the Company had the following outstanding warrants to purchase common stock:
| Warrant | Issuance Date | Expiration Date | Exercise Price Per Share ($) | Number of Underlying Common Stocks |
|---|---|---|---|---|
| March 2021 Warrants | March 29, 2021 | March 31, 2026 | 10.35 | 2,469,156 |
| March 2023 Warrants | March 27, 2023 | March 26, 2026 | 5.50 | 3,294,117 |
-15-
NOTE 5 – EQUITY(continued):
b. Stock-based compensation for employees, directors and service providers:
In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “2020 Plan”).
The 2020 Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the 2020 Plan by an additional 777,778 shares of common stock. During the first quarter of 2023, the Company’s Board of Directors approved an increase to the option pool pursuant to the 2020 Plan by an additional 1,000,000 shares of common stock.
In June 2024, the Company’s Board of Directors approved the 2024 Share Incentive Plan (the “2024 Plan”). With adoption of the 2024 Plan, the Company ceased making new awards under the 2020 Plan.
The 2024 Plan initially included a pool of 234,484 shares of common stock, representing the number of shares remaining available for grant under the 2020 Plan. These shares are available for future grant to Company employees, consultants, directors and other service providers. Shares that were subject to awards granted under either the 2020 Plan or the 2024 Plan that have expired or were cancelled or become un-exercisable for any reason without having been exercised in full shall become available for future grant under the 2024 Plan.
In July 2024, the Company’s Board of Directors approved an increase to the 2024 Plan’s option pool by an additional 850,000 shares of common stock.
Also in July 2024, stockholders approved the 2024 Plan.
The 2020 Plan and 2024 Plan each provide for the grant of stock options (including incentive stock options and nonqualified stock options), shares of common stock, restricted shares, restricted share units, and other share-based awards.
Stock option activity
The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:
| Six months ended | |
|---|---|
| Underlying value of ordinary shares ($) | 5.12 |
| Exercise price ($) | 6.50 |
| Expected volatility (%) | 99.65% |
| Term of the options (years) | 7 |
| Risk-free interest rate | 4.10% |
The cost of the benefit embodied in the options granted during the six months ended June 30, 2025, based on their fair value as of the grant date, is estimated to be approximately $926 thousand. These amounts will be recognized in the statements of operations and comprehensive income over the vesting period.
The following table summarizes stock option activity for the six months ended June 30, 2025:
| For the | ||
|---|---|---|
| Six months ended | ||
| Number of | Weighted average | |
| Options | exercise price ($) | |
| Outstanding at beginning of period | 3,227,234 | 3.78 |
| Granted | 181,000 | 6.5 |
| Exercised | (58,101) | 3.27 |
| Forfeited | (28,336) | 4.09 |
| Outstanding at end of period | 3,321,797 | 3.94 |
| Vested at end of period | 2,035,607 | 3.52 |
-16-
NOTE 5 – EQUITY(continued):
Restricted stock unit (“RSU”) activity
Each RSU vests based on continued service to the Company, generally over three years. The grant date fair value of the award is recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.
The following table summarizes RSU activity for the six months ended June 30, 2025:
| For the | ||
|---|---|---|
| Six months ended | ||
| Number of | Weighted Average Grant Date Fair Value | |
| RSUs | per Share ($) | |
| Outstanding at beginning of period | 15,419 | 3.56 |
| Granted | - | - |
| Forfeited | - | - |
| Vested | (7,085) | 4.21 |
| Unvested and Outstanding at end of period | 8,334 | 3 |
The following table sets forth the total stock-based payment expenses resulting from options and RSUs granted, included in the statements of operation and comprehensive income:
| Six months ended June 30, | Three months ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Unaudited | ||||
| USD in thousands | ||||
| Cost of revenues | (3) | 17 | - | 8 |
| Research and development | 466 | 225 | 219 | 90 |
| Sales and marketing expenses | 202 | 95 | 99 | 45 |
| General and administrative | 986 | 626 | 527 | 320 |
| Total expenses | 1,651 | 963 | 845 | 463 |
-17-
NOTE 6 –REVENUES:
| a. | Disaggregation of revenue: |
| (1) | During the second quarter of 2022, the Company completed the development of a customer-specific project for a Fortune 500 medical company customer (the “Client”) and moved from the project development phase to its production phase. Through June 30, 2025, the Company recognized development services revenues and costs that had been previously deferred based on the expected manufacturing term of the product, which the Company estimated originally at seven years. During the first quarter of 2025, due to the fact that the Company has not received a purchase order from the Client and does not expect to receive such order, the Company decided to fully derecognize the fulfillment asset and contract liability associated with the Client, in the amount of $1,690 thousand and $957 thousand, respectively. |
| (2) | During the six months ended June 30, 2025, the Company recognized revenues from customization and development services in which the performance obligation is satisfied over time in the amount of $569 thousand. |
| b. | Contract fulfillment assets and Contract liabilities: |
The Company’s contract fulfillment assets and contract liabilities as of June 30, 2025, and December 31, 2024, were as follows:
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| USD in thousands | ||
| Contract fulfillment assets | - | 1,017 |
| Contract liabilities | 279 | 2,075 |
Contract liabilities include deferred service and advance payments.
The change in contract fulfillment assets:
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| USD in thousands | ||
| Balance at beginning of the period | 1,017 | 1,256 |
| Contract costs recognized during the period | (1,017) | (239) |
| Balance at end of the period | - | 1,017 |
The change in contract liabilities:
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| USD in thousands | ||
| Balance at beginning of the period | 2,075 | 2,322 |
| Deferred revenue relating to new sales | 178 | 253 |
| Revenue recognized during the period | (1,974) | (500) |
| Balance at end of the period | 279 | 2,075 |
Remaining Performance Obligations
Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be invoiced and recognized as revenue in future periods. As of June 30, 2025, the total RPO amounted to approximately $14.4 million.
-18-
NOTE 7 -INVENTORY:
Composed as follows:
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| USD in thousands | ||
| Raw materials and supplies | - | 172 |
| Work in progress | - | 19 |
| Finished goods | - | 12 |
| Inventory gross | - | 203 |
For the six months ended June 30, 2025, the Company recognized an inventory impairment related to the Client in the amount of $203 thousand. See Note 6a(1).
NOTE 8 –LOSS PER SHARE
Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares as described below.
Basic net loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the common stock considered outstanding during the year, in accordance with ASC 260-10 “Earnings per Share”.
All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the period, since all such securities have an anti-dilutive effect.
NOTE 9 -COMMITMENTS AND CONTINGENCIES
On April 2023, the Company received approval from the Israel Innovation Authority (the “IIA”) to support and enhance the Company’s production line and capabilities in the next 24 months until April 2025. Pursuant to the agreement with the IIA relating to the program, the Company is required pay royalties of 3% to the IIA up to the amount IIA funding received and the accrued interest repayment of the grant is contingent upon the Company successfully completing its enhancement plans and generating sales from the enhancements performed. The Company has no obligation to repay these grants if its enhancement plans are not completed or aborted or if it generates no sales.
-19-
NOTE 10 –SEGMENT REPORTING
Segment information is prepared on the same basis that the chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes business decisions and assesses performance. The Company has one reportable segment specializing in vision-based platform solutions as described in Note 1.
The chief executive officer assesses performance for this segment and decides how to allocate resource. The measure of segment assets is reported on the balance sheet as total assets. The chief executive officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor budget versus actual results.
The table below summarizes the significant expense categories regularly reviewed by the chief operating decision maker, for the six months and three months ended June 30, 2025 and 2024:
| Six months ended June 30, | Three months ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Unaudited | ||||
| USD in thousands | ||||
| Revenues | 2,427 | 1,368 | 362 | 1,181 |
| Cost of Sales (*) | 1,749 | 1,038 | 229 | 649 |
| Research and Development expenses (*) | 4,340 | 2,722 | 2,112 | 1,303 |
| Sales and marketing (*) | 820 | 364 | 527 | 180 |
| General and Administrative expenses (*) | 2,807 | 1,945 | 1,056 | 919 |
| Other segment items: | ||||
| Stock-based payments | 1,651 | 963 | 845 | 463 |
| Depreciation | 58 | 64 | 31 | 31 |
| Finance income, net | 658 | 384 | 363 | 182 |
| Net loss | (8,340) | (5,344) | (4,075) | (2,182) |
| (*) | Excluding stock-based payments and depreciation expenses. |
|---|
NOTE 11 –SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued and identified no subsequent events as of the date that the financial statements were issued.
-20-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.